Warning: count(): Parameter must be an array or an object that implements Countable in /home/logicben/public_html/drugtrialsformoney.com/wp-content/plugins/redux-framework/redux-core/inc/classes/class-redux-output.php on line 390

Safety of Intravenous Allogeneic Engineered Natural Killer Cells in Adults With AML or MDS

Safety of Intravenous Allogeneic Engineered Natural Killer Cells in Adults With AML or MDS
Conditions:   Relapsed/Refractory AML;   AML, Adult;   MDS;   Refractory Myelodysplastic Syndromes
Intervention:   Biological: NKX101 – CAR NK cell therapy
Sponsor:   Nkarta Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

November 11, 2020 / by / in
Comments